In this setting, under the selective pressure from highly potent AR-targeted therapies, PCa cells gradually reduce the dependency on AR signaling, lose their original luminal epithelial identity, and acquire a NE phenotype2–4,7. The gene discussed is AR; the disease is posterior cortical atrophy.